about
Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine targetGene therapy for metachromatic leukodystrophy.Fate of systemically administered cocaine in nonhuman primates treated with the dAd5GNE anticocaine vaccineCocaine analog coupled to disrupted adenovirus: a vaccine strategy to evoke high-titer immunity against addictive drugs.Novel cocaine vaccine linked to a disrupted adenovirus gene transfer vector blocks cocaine psychostimulant and reinforcing effectsGenetic modification of neurons to express bevacizumab for local anti-angiogenesis treatment of glioblastoma.Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological functionIn vivo gene transfer strategies to achieve partial correction of von Willebrand disease.Anti-Epidermal Growth Factor Receptor Gene Therapy for GlioblastomaConfronting the issues of therapeutic misconception, enrollment decisions, and personal motives in genetic medicine-based clinical research studies for fatal disorders.Transfer of the AQP1 cDNA for the correction of radiation-induced salivary hypofunction.Disrupted adenovirus-based vaccines against small addictive molecules circumvent anti-adenovirus immunity.AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessationBrain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease).Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.AAV-mediated persistent bevacizumab therapy suppresses tumor growth of ovarian cancer.Radioiodinated Capsids Facilitate In Vivo Non-Invasive Tracking of Adeno-Associated Gene Transfer Vectors.In situ reprogramming to transdifferentiate fibroblasts into cardiomyocytes using adenoviral vectors: Implications for clinical myocardial regeneration.Gene therapy to stimulate angiogenesis to treat diffuse coronary artery disease.Efficacy of an adenovirus-based anti-cocaine vaccine to reduce cocaine self-administration and reacqusition using a choice procedure in rhesus macaques.Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations.Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice.Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy.Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models.Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab.Evaluation of compounded bevacizumab prepared for intravitreal injection.Phase I/II study of intrapleural administration of a serotype rh.10 replication-deficient adeno-associated virus gene transfer vector expressing the human α1-antitrypsin cDNA to individuals with α1-antitrypsin deficiency.Comparative efficacy and safety of multiple routes of direct CNS administration of adeno-associated virus gene transfer vector serotype rh.10 expressing the human arylsulfatase A cDNA to nonhuman primates."Triplet" polycistronic vectors encoding Gata4, Mef2c, and Tbx5 enhances postinfarct ventricular functional improvement compared with singlet vectors.Intrapleural administration of an AAVrh.10 vector coding for human α1-antitrypsin for the treatment of α1-antitrypsin deficiency.Differences in hydrogen exchange behavior between the oxidized and reduced forms of Escherichia coli thioredoxin.Reduction of thioredoxin significantly decreases its partial specific volume and adiabatic compressibility.Double-blinded, placebo-controlled, randomized gene therapy using surgery for vector delivery.Intracranial delivery of CLN2 reduces brain pathology in a mouse model of classical late infantile neuronal ceroid lipofuscinosis.AAV2-mediated CLN2 gene transfer to rodent and non-human primate brain results in long-term TPP-I expression compatible with therapy for LINCL.Safety of direct administration of AAV2(CU)hCLN2, a candidate treatment for the central nervous system manifestations of late infantile neuronal ceroid lipofuscinosis, to the brain of rats and nonhuman primates.P12-14. Design of hydrophilic, helical peptides that mimic the 4E10 epitope of HIV-1 gp41.Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats.Evaluation of a Lipopeptide Immunogen as a Therapeutic in HIV Type 1-Seropositive IndividualsHIV-1 rational vaccine design: molecular details of b12-gp120 complex structure
P50
Q29547347-0F778946-3269-4A0A-966E-2DB4F1CC84D5Q30357745-C3C009A4-8D27-4E47-BAC0-987D896ABE35Q33720616-D154E595-CE2E-4314-811F-A6C98B21CE33Q34157554-38C688EE-9B67-4429-B8DE-E15156D9885AQ34216479-AB6B3959-E80D-4A0F-9E16-B1D37517CECEQ34943946-97421BCD-6EDE-4C58-A009-537B5C05FDEDQ34981680-F5203E08-3E53-4C1F-B94A-D13FC4E0C84AQ36084450-F1C2E2B6-2632-4762-BE71-7CE854AA174FQ36155208-4D434FDA-6AFF-4D50-8C80-5FEAA1DC8C37Q36252231-FB324B6E-B041-4DA0-B68C-C697DA121342Q36347957-9D41C457-520D-44DB-AF24-C42110D4260BQ36562614-09E20772-FCA4-4D75-A0C0-DBB63E22B35CQ36756701-40C4F7D5-D8B2-455A-9788-EA53E7A9032CQ37004315-D6EFB7BE-BF00-4497-B4D4-77692970A42CQ37172714-C29B82AB-69DE-4597-B8D2-864CC94F6E5EQ37374843-E2BBB1C9-7A55-41CC-B796-B6847A36B180Q37563484-22113FE9-CF31-4E41-A3AE-CF31055B607EQ37631284-33623859-61F6-4919-8407-537D1DFEC3E3Q38155896-135A907B-56F2-478F-8E59-081FC9C82C30Q39327496-B5ECC17D-8497-4804-9D41-1BAE4564B467Q39851951-60B78B79-4BF4-4810-B35E-ADD96E3BBCBAQ40436587-8102B8DD-A307-4C89-8EA9-5CAE14D3BD70Q40669769-425F6850-AE19-4BF6-B879-CA5161624B5FQ40693796-BC46861D-2221-4271-B790-78712EFA6990Q41091625-E70314E5-0C55-483D-B481-C5BF6EC70D35Q41734573-CBAC9809-9A48-4D59-9636-1A0C189052C7Q42186744-4B8DCA97-0711-4B88-825E-C023591CD406Q42198683-7DEE3E06-34B0-40BF-A185-7EC744796F28Q42222974-114DC42B-6CB7-43A4-8E0A-9A3EBE8DF1CAQ42257689-889DCE95-44BF-4E7E-9553-B25594B2F6C0Q42841798-DCC69200-5660-45A5-9F93-67FA85165F0BQ42841808-E6DC7566-6F57-404E-8A75-86C4D24A33E7Q44420553-A1F900D4-022E-4C75-AC0B-4F6E4B364764Q45026873-A88FBF89-5787-4A16-9017-F8B9F899188FQ45885520-0E15241F-77EE-4A8A-B3E5-0C819EE3E81BQ45889555-2399C455-58FB-437B-AFA5-CB21AD40509AQ46988625-6017444A-328C-458D-A6ED-CD4C9283A3D7Q50974761-C0182DC7-77C3-48DF-AB30-6F4F78BA5CABQ57080567-37EAEDF2-2517-49DE-8D5A-CFFCDFEE2629Q80416564-4AB765AA-96BE-4166-8F60-B87680652D3F
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stephen M. Kaminsky
@ast
Stephen M. Kaminsky
@en
Stephen M. Kaminsky
@es
Stephen M. Kaminsky
@sl
type
label
Stephen M. Kaminsky
@ast
Stephen M. Kaminsky
@en
Stephen M. Kaminsky
@es
Stephen M. Kaminsky
@sl
prefLabel
Stephen M. Kaminsky
@ast
Stephen M. Kaminsky
@en
Stephen M. Kaminsky
@es
Stephen M. Kaminsky
@sl
P1053
J-5141-2016
P106
P1153
7005688198
P21
P31
P3829
P496
0000-0003-1869-834X